Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 63

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Colitis ulcerative

Not yet recruiting

Study on the Safety and Effectiveness of Lutikizumab and Adalimumab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Rheumatoid arthritis

Not yet recruiting

Study comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:Mabxience Research S.L.

Erythema multiforme

Not yet recruiting

Study on Severe Erythema Multiforme: Comparing Methylprednisolone Acetate and Lidocaine Hydrochloride Monohydrate with Placebo for Hospitalized Patients

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Assistance Publique Hopitaux De Paris

Hypersensitivity

Not yet recruiting

Study on the Effectiveness of Dermatophagoides Allergen Extracts for Allergy Patients Using Dermatophagoides Pteronyssinus and Dermatophagoides Farinae Solutions

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Advanced Outcomes Research S.L.

Colitis ulcerative

Not yet recruiting

Study on the Effects of Adalimumab, Vedolizumab, and Tofacitinib on Heart Health in Patients with Ulcerative Colitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Cardiac amyloidosis

Not yet recruiting

Study on Heart Amyloidosis Using Sodium Fluoride (18F) and Iodine (123I) Iobenguane for Patients with Transthyretin Amyloid Cardiomyopathy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Iodine (123I) Iobenguane
  • Sponsor:Universitair Medisch Centrum Groningen

Cardiac sarcoidosis

Not yet recruiting

Detecting Heart Inflammation in Cardiac Sarcoidosis Patients Using 68Ga-NOTA-Anti-MMR-VHH2 PET-CT Imaging

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nanobody Against Macrophage Mannose Receptor, Conjugated With 1,4,7-Triazacyclononane-N,N',N''-Triacetic Acid, Labelled With Gallium Ga-68
  • Sponsor:Cliniques Universitaires Saint-Luc

Interstitial lung disease+1

Not yet recruiting

Study of tezepelumab in patients with progressive pulmonary fibrosis and increased eosinophil levels in blood

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:Philipps-Universitaet Marburg

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Food allergy

Not yet recruiting

Study on the Safety and Tolerability of INP20 for Peanut Allergy in Patients

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Innoup Farma S.L.

Multiple sclerosis

Not yet recruiting

Study on the Effects of Semaglutide and Dulaglutide in Adults with Multiple Sclerosis Aged 18-60 with High Disease Activity

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years
  • Substances:Dulaglutide
  • Sponsor:Comenius University Bratislava

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.